No biomarker	Juvenile Myelomonocytic Leukemia	No biomarker	Juvenile Myelomonocytic Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
PTPN11 mutation	Juvenile Myelomonocytic Leukemia	PTPN11 mutation	Juvenile Myelomonocytic Leukemia	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS mutation	Juvenile Myelomonocytic Leukemia	KRAS mutation	Juvenile Myelomonocytic Leukemia	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4
ETV6-FLT3 fusion	Juvenile Myelomonocytic Leukemia	ETV6-FLT3 fusion	Juvenile Myelomonocytic Leukemia	gilteritinib Sensitive: C4 – Case Studies gilteritinib Sensitive : C4	gilteritinib Sensitive: C4 – Case Studies gilteritinib Sensitive : C4
SETBP1 mutation + NRAS mutation	Juvenile Myelomonocytic Leukemia	SETBP1 mutation + NRAS mutation	Juvenile Myelomonocytic Leukemia	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D

Juvenile Myelomonocytic Leukemia

Associations(5)